1Nation Health Commission of China. Update on COVID–19, <http://www.nhc.gov.cn/xcs/yqfkdt/202003/ec2689b0e716468fbfff7cf890c74bb7.shtml> (2020).
2WHO. WHO Director General’s remarks at the G20 Extraordinary Leaders’ Summit on COVID–19 - 26 March 2020, <https://www.who.int/zh/dg/speeches/detail/who-director-general-s-remarks-at-the-g20-extraordinary-leaders-summit-on-covid–19—–26-march–2020> (2020).
3WHO. WHO director general’s opening remarks at the media briefing on covid–19 - 11 march 2020, <https://www.who.int/zh/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid–19—–11-march–2020> (2020).
4Nation Health Commission of China. Guidelines for diagnosis and treatment of COVID–19(7th ed), <http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml> (2020).
5Wang, D. et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, doi:10.1001/jama.2020.1585 (2020).
6Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, doi:10.1016/s0140–6736(20)30211–7 (2020).
7Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, doi:10.1016/s0140–6736(20)30183–5 (2020).
8Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID–19 in Wuhan, China: a retrospective cohort study. The Lancet 395, 1054–1062, doi:10.1016/s0140–6736(20)30566–3 (2020).
9Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV–2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine, doi:10.1016/s2213–2600(20)30079–5 (2020).
10Xu, Z. et al. Pathological findings of COVID–19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine, doi:10.1016/s2213–2600(20)30076-x (2020).
11Zheng, M. et al. Functional exhaustion of antiviral lymphocytes in COVID–19 patients. Cell. Mol. Immunol., doi:10.1038/s41423–020–0402–2 (2020).
12Lin, L., Lu, L., Cao, W. & Li, T. Hypothesis for potential pathogenesis of SARS-CoV–2 infection–a review of immune changes in patients with viral pneumonia. Emerging Microbes & Infections 9, 727–732, doi:10.1080/22221751.2020.1746199 (2020).
13Seymour, C. W. et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis–3). JAMA 315, 762–774, doi:10.1001/jama.2016.0288 (2016).
14Raith, E. P. et al. Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care Unit. Jama 317, 290, doi:10.1001/jama.2016.20328 (2017).
15Mehta, P. et al. COVID–19: consider cytokine storm syndromes and immunosuppression. The Lancet 395, 1033–1034, doi:10.1016/s0140–6736(20)30628–0 (2020).
16Russell, C. D., Millar, J. E. & Baillie, J. K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet 395, 473–475, doi:10.1016/s0140–6736(20)30317–2 (2020).
17Li, G. & De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 19, 149–150, doi:10.1038/d41573–020–00016–0 (2020).